Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 5:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 124 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Liver Transplant Infection Clear all
Completed No phase listed Observational

Cell Mediated Immunity With Risk of Cytomegalovirus (CMV) in Solid Organ Transplant Recipients

NCT01558037
View directory record Official record
Conditions
Awaiting Organ Transplant, Infection in Solid Organ Transplant Recipients
Interventions
Not listed
Lead sponsor
Michael Ison
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Sep 22, 2026, 5:11 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor

NCT02639247
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL/VOX, SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
43
States / cities
Long Beach, California • Los Angeles, California • Palo Alto, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 22, 2026, 5:11 PM EDT
Withdrawn Phase 4 Interventional

Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1

NCT02485080
View directory record Official record
Conditions
PT-NANBH
Interventions
Simeprevir, Sofosbuvir
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 72 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Palo Alto, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 12, 2016 · Synced Sep 22, 2026, 5:11 PM EDT
Terminated Phase 2 Interventional Results available

An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients

NCT01467505
View directory record Official record
Conditions
Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a, Immunosuppressant Regimen
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2015 · Synced Sep 22, 2026, 5:11 PM EDT
Completed Phase 2 Interventional Results available

A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV

NCT02138253
View directory record Official record
Conditions
Liver Fibrosis, Hepatic Fibrosis, Liver Cirrhosis, Hepatic Cirrhosis
Interventions
IDN-6556, Placebo
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
35
States / cities
Coronado, California • La Jolla, California • Loma Linda, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Sep 22, 2026, 5:11 PM EDT
Completed Phase 4 Interventional Results available

CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL")

NCT01552369
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
Valganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
6
States / cities
Los Angeles, California • Atlanta, Georgia • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Sep 22, 2026, 5:11 PM EDT
Completed No phase listed Observational

Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy

NCT01590615
View directory record Official record
Conditions
Hepatitis B
Interventions
Anti-HBV nucleoside/nucleotide therapy
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
23
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2017 · Synced Sep 22, 2026, 5:11 PM EDT
Completed Phase 4 Interventional Results available

Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?

NCT01101750
View directory record Official record
Conditions
Cervical Cancer, Hpv, Warts
Interventions
Quadrivalent HPV for types 6, 11, 16 and 18
Biological
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
9 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 22, 2026, 5:11 PM EDT
Recruiting No phase listed Observational

Expanding HOPE Liver

NCT07778459
View directory record Official record
Conditions
HIV Infection, Liver Transplant
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 22, 2026, 5:11 PM EDT
Completed Phase 2 Interventional

Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection

NCT01435044
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Sofosbuvir, GS-0938, RBV, Placebo to match sofosbuvir, Placebo to match GS-0938
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
42
States / cities
Montgomery, Alabama • Bakersfield, California • Coronado, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2014 · Synced Sep 22, 2026, 5:11 PM EDT
Completed Phase 2 Interventional Results available

The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients

NCT03819322
View directory record Official record
Conditions
Liver Transplant, Hepatitis C
Interventions
sofosbuvir/velpatasvir
Drug
Lead sponsor
Fernanda P Silveira, MD, MS
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 22, 2026, 5:11 PM EDT
Completed Phase 4 Interventional Results available

Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant

NCT02533934
View directory record Official record
Conditions
HIV, Hepatitis C, Cirrhosis
Interventions
Harvoni
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
8
States / cities
San Francisco, California • Washington D.C., District of Columbia • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 22, 2026, 5:11 PM EDT
Completed Phase 2 Interventional

Expanding the Pool in Orthotopic Heart Transplantation

NCT03222531
View directory record Official record
Conditions
Hepatitis C, Heart Transplant, Cardiac Transplant
Interventions
sofosbuvir/velpatasvir
Drug
Lead sponsor
Mary E. Keebler, MD
Other
Eligibility
18 Years to 71 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 22, 2026, 5:11 PM EDT
Completed Phase 3 Interventional

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

NCT01804829
View directory record Official record
Conditions
Hepatitis C Infection, Viruses, Hepatocellular Carcinoma, Hepatitis, Viral, Human, Liver Cirrhosis
Interventions
Civacir® 10%
Biological
Lead sponsor
Biotest Pharmaceuticals Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
23
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Sep 22, 2026, 5:11 PM EDT
Completed No phase listed Observational

Effectiveness of the Hepatitis B Vaccine Post-Hematopoietic Stem Cell Transplant

NCT03511794
View directory record Official record
Conditions
Hepatitis B
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
4 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 6, 2022 · Synced Sep 22, 2026, 5:11 PM EDT
Completed Phase 4 Interventional Results available

PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.

NCT00087633
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
peginterferon alfa-2a [Pegasys], Copegus
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 22, 2026, 5:11 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Adefovir Plus Vaccination in Transplant Patients Without Hepatitis B That Receive a Core Antibody Positive Liver

NCT01146808
View directory record Official record
Conditions
Hepatitis B, Liver Transplantation
Interventions
Adefovir dipivoxil and hepatitis B vaccination
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Sep 22, 2026, 5:11 PM EDT
Terminated Not applicable Interventional Results available

Mild Hypothermia and Acute Kidney Injury in Liver Transplantation

NCT03534141
View directory record Official record
Conditions
Cirrhosis, End Stage Liver Disease, Acute Kidney Injury, Liver Transplant; Complications, Chronic Kidney Diseases, Hepatitis c, Hepatitis B, NASH - Nonalcoholic Steatohepatitis, Alcoholic Cirrhosis, Hepatocellular Carcinoma
Interventions
Esophageal cooling/warming device, Mild hypothermia, Normothermia
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
San Francisco, California • Aurora, Colorado • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 22, 2026, 5:11 PM EDT
Suspended Not applicable Interventional

Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation

NCT02935478
View directory record Official record
Conditions
Obesity, Weight Loss, Body Weight, Hepatocellular Carcinoma, HCC, Hepatitis C, Cirrhosis
Interventions
Embospheres Microspheres
Device
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Sep 22, 2026, 5:11 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer

NCT00002515
View directory record Official record
Conditions
Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma, Testicular Germ Cell Tumor
Interventions
filgrastim, carboplatin, thiotepa, topotecan hydrochloride, autologous bone marrow transplantation, bone marrow ablation with stem cell support, in vitro-treated bone marrow transplantation
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Sep 22, 2026, 5:11 PM EDT
Enrolling by invitation Phase 3 Interventional

Rezafungin Prophylaxis in Liver Transplant

NCT06774144
View directory record Official record
Conditions
Liver Transplant Infection, Fungal Infection
Interventions
Rezafungin, Standard of care antifungal prophylaxis
Drug
Lead sponsor
Fernanda P Silveira, MD, MS
Other
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 22, 2026, 5:11 PM EDT
Terminated Phase 2 Interventional Results available

Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C

NCT01532908
View directory record Official record
Conditions
Hepatitis C Infection
Interventions
MBL-HCV1, Telaprevir (Part 1), Sofosbuvir (Part 2)
Biological · Drug
Lead sponsor
MassBiologics
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Boston, Massachusetts • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Sep 22, 2026, 5:11 PM EDT
Completed No phase listed Observational

Adult-to-Adult Living Donor Transplant Cohort Study

NCT01619475
View directory record Official record
Conditions
Liver Diseases, Hepatocellular Cancer, End Stage Liver Disease, Hepatitis C, Liver Cirrhosis
Interventions
Not listed
Lead sponsor
Arbor Research Collaborative for Health
Other
Eligibility
18 Years and older
Enrollment
1,871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Sep 22, 2026, 5:11 PM EDT
Completed Phase 1 Interventional

A Pilot Study to Examine the Role of Nitazoxanide to Prevent Recurrence of Hepatitis C After Transplantation

NCT01074203
View directory record Official record
Conditions
Hepatitis C Recurrence
Interventions
Nitazoxanide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Sep 22, 2026, 5:11 PM EDT